With a huge market at stake, GlaxoSmithKline says it will mount a head-to-head study of its cervical cancer vaccine Cervarix [1] against Merck's Gardasil. The Phase III trial involves 1,042 volunteers in two arms, each taking one of the two vaccines. The trial will compare the immune response of 18 to 24-year-old women to two types of human papillomavirus. Secondary objectives are laid out for immune responses among older women.
- check out GSK's press release [2]
- read the AFX report [3] on the trial
PLUS: The Guardian covers the development of a new generation of virus-vectored vaccines that promise to take on a number of diseases like malaria [4]. Report [5]
Related Articles:
Merck's Gardasil OK'd for pricey rollout. Report [6]
Cervarix more effective in girls aged 10-14. Report [1]
Merck's McGlynn has key role developing vaccines. Report [7]
Links:
[1] http://www.fiercebiotech.com/story/cervarix-more-effective-in-girls-aged-10-14/2005-12-19
[2] http://www.fiercebiotech.com/node/5273
[3] http://www.forbes.com/markets/feeds/afx/2007/01/18/afx3338347.html
[4] http://www.fiercebioresearcher.com/story/genome-map-completed-on-malaria-parasite/2006-12-14
[5] http://www.fiercebioresearcher.com/story/new-approach-to-vaccine-development/2007-01-18
[6] http://www.fiercebiotech.com/story/merck-s-gardasil-ok-d-for-pricey-rollout/2006-06-09
[7] http://www.fiercebiotech.com/story/merck-s-mcglynn-has-key-role-developing-vaccines/2007-01-02